Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding

Rhea-AI Filing Summary

Syndax Pharmaceuticals Inc Chief Financial Officer Keith A. Goldan reported an open-market sale of 1,177 shares of common stock at $18.99 per share. According to the footnote, these shares were required to be sold to cover tax withholding obligations from the vesting of restricted stock units. Following the transaction, he held 139,252 shares directly, indicating this was a small, tax-related adjustment rather than a large discretionary sale.

Insider Trade Summary

Net Seller: 1,177 shares ($22,351)

Net Sell 1 txn

Insider Goldan Keith A.

Role Chief Financial Officer

Sold 1,177 shs ($22K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,177	$18.99	$22K

Holdings After Transaction: Common Stock — 139,252 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,177 shares Sale price: $18.99 per share Shares held after sale: 139,252 shares

3 metrics

Shares sold 1,177 shares Open-market sale to cover tax withholding on RSU vesting

Sale price $18.99 per share Price for the 1,177 Syndax common shares sold

Shares held after sale 139,252 shares Direct ownership by CFO Keith A. Goldan following the transaction

Key Terms

restricted stock units, tax withholding obligations, open-market sale

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goldan Keith A.

(Last) (First) (Middle)

730 THIRD AVENUE

FLOOR 9

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Syndax Pharmaceuticals Inc [ SNDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S(1)		1,177	D	$18.99	139,252	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Michael A. Metzger, Attorney-in-Fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Syndax (SNDX) report for its CFO?

Syndax reported that CFO Keith A. Goldan sold 1,177 shares of common stock. The sale was made at $18.99 per share to cover tax withholding from vesting restricted stock units, a routine administrative transaction rather than a large discretionary sale.

At what price did the Syndax (SNDX) CFO’s Form 4 shares sell?

The 1,177 Syndax shares sold by CFO Keith A. Goldan were transacted at $18.99 per share. This price applies to the entire reported sale, which was executed to satisfy tax withholding obligations tied to restricted stock unit vesting.

How many Syndax (SNDX) shares does the CFO hold after this Form 4 sale?

After selling 1,177 shares, CFO Keith A. Goldan directly holds 139,252 Syndax common shares. This shows the sale covered tax obligations from restricted stock unit vesting while leaving a substantial remaining equity position in the company.

Why did the Syndax (SNDX) CFO sell 1,177 shares according to the Form 4?

The Form 4 footnote explains that 1,177 shares were required to be sold to cover tax withholding obligations. These obligations arose from the vesting of restricted stock units, making the sale a tax-related administrative event rather than a discretionary portfolio decision.

What does the Form 4 transaction code mean for Syndax (SNDX) CFO’s sale?

The Form 4 uses code “S,” indicating a sale in an open market or private transaction. However, the footnote clarifies the sale’s purpose was to cover tax withholding from restricted stock unit vesting, which typically carries weaker informational value for investor sentiment.